Ascendis Pharma A/S (ASND) Financials

ASND Assets vs Liabilities
DateAssetsLiabilities
March 31, 2026 2.3 billion 1.7 billion
Dec. 31, 2025 1.5 billion 1.7 billion
Sept. 30, 2025 1.4 billion 1.6 billion
June 30, 2025 1.3 billion 1.5 billion

ASND Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
March 31, 2026 -18.0 million 34.8 million
Dec. 31, 2025 79.1 million 35.2 million
Sept. 30, 2025 2.5 million 36.0 million
June 30, 2025 -13.8 million 35.4 million

ASND Net Income

No data available :(

ASND Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
March 31, 2026 657.1 million 442.9 million -
Dec. 31, 2025 722.9 million 452.1 million -
Sept. 30, 2025 632.6 million 388.9 million -
June 30, 2025 582.3 million 389.2 million -

ASND Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
March 31, 2026 73.9 million
Dec. 31, 2025 72.1 million
Sept. 30, 2025 71.6 million
June 30, 2025 75.3 million

ASND Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
March 31, 2026 9.0 million 66.0 million 167.5 million -
Dec. 31, 2025 3.9 million 88.0 million 156.4 million -
Sept. 30, 2025 62197 78.5 million 131.1 million -
June 30, 2025 5.1 million 84.8 million 124.6 million -

ASND Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
March 31, 2026 287.2 million 24.8 million
Dec. 31, 2025 287.8 million 31.9 million
Sept. 30, 2025 250.7 million 26.2 million
June 30, 2025 186.3 million 37.1 million

ASND

Price: $212.78

52 week price:
150.89
250.74

Earnings Per Share: 8.82 USD

P/E Ratio: 24.81

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: Denmark

Volume: 126716

Ebitda: -36.5 million

Market Capitalization: 13.5 billion

Links: